Acronycine revisited: Development of benzo[b]acronycine antitumor agents;De l'acronycine aux dérivés de la benzo[b]acronycine: Conception et développement d'une nouvelle série d'antitumoraux

Annales Pharmaceutiques Francaises

Volumn 63, Issue 1, 2005, Pages 35-43

  Tillequin, Fr ^a   Koch, M ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Acronycine; Alkylating agent; Antitumor activity; S23906; Sarcomelicope

Indexed keywords

1,2 DIACETOXY 1,2 DIHYDROBENZ[B]ACRONYCINE; 1,2 DIHYDROXY 1,2 DIHYDROACRONYCINE; ACRONINE; ANTINEOPLASTIC AGENT; BENZ[B]ACRONYCINE; S 239061; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CHEMICAL BOND; CLINICAL TRIAL; CORRELATION ANALYSIS; CYTOTOXICITY; DRUG ACTIVITY; DRUG DNA BINDING; DRUG POTENCY; DRUG SOLUBILITY; HUMAN; IN VIVO STUDY; NUDE MOUSE; SOLID TUMOR; STRUCTURE ACTIVITY RELATION;

EID: 14244265661     PISSN: 00034509     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0003-4509(05)82249-7     Document Type: Article

References (26)

1. Hughes GK, Lahey FN, Price JR. Alkaloids of the Australian Rutaceae. Nature 1948; 162: 223-4.
2. Hartley TG. A revision of the genus Sarcomelicope (Rutaceae). Aust J Bot 1982; 30: 359-72.
3. Tillequin F, Michel S, Skaltsounis AL. Acronycine type alkaloids: chemistry and biology in Pelletier SW Ed: Alkaloids: Chemical and Biological Perspectives, Amsterdam: Elsevier: 1998; 12: 1-102.
4. Macdonald PL, Robertson AV. The structure of acronycine. Aust J Chem 1966; 19: 275-81.
5. Svoboda GH. Alkaloids of Acronichia baueri - Extraction of the alkaloids and structure - activity relationships. Lloydia 1966; 29: 206-24.
6. Svoboda GH, Poore GA, Simpson PJ, Boder GB. Alkaloids of Acronychia baueri - Isolation of the alkaloids and study of the antitumor and other biological properties of acronycine. J Pharm Sci 1966; 55: 758-68.
7. Scarffe JH, Beaumont AR, Crowther D. Phase I-II evaluation of acronycine in patients with multiple myeloma. Cancer Treat Rep 1983; 67: 93-4.
8. Michel S, Tillequin F, Seguin E. Structure-activity relationships in the acronycine series. Curr Med Chem 2002; 9: 1241-53.
9. Schneider J, Evans EL, Grunberg E, Fryer RI. Synthesis and biological activity of acronycine analogs. J Med Chem 1972; 15: 266-70.
10. Brum-Bousquet M, Mitaku S, Skaltsounis AL, Tillequin F, Koch M. Acronycine epoxide: a new acridone alkaloid from several Sarcomelicope species. Planta Med 1988; 54: 470-1.
11. Bowers SW. How anti-juvenile hormones work. Amer Zool 1981; 21: 737-42.
12. Elomri A, Mitaku S, Michel S, Skaltsounis AL, Tillequin F, Koch M, et al. Synthesis and cytotoxic and antitumor activity of esters in the 1,2-dihydroxy-1,2-dihydroacronycine series. J Med Chem 1996; 39: 4762-6.
13. Magiatis P, Mitaku S, Skaltsounis AL, Tillequin F, Koch M, Pierré A. Synthesis and biological activity of esters in the trans-1,2-dihydroxy-1,2- dihydroacronycine series. J Nat Prod 1998; 61: 198-201.
14. Costes N, Michel S, Tillequin F, Koch M, Pierré A, Atassi Gh. Chiral dihydroxylation of acronycine: absolute configuration of natural cis-1,2-dihydroxy-1,2-dihydroacronycine and cytotoxicity of (1R, 2R)- and (1S, 2S)-1,2-diacetoxy-1,2-dihydroacronycine. J Nat Prod 1999; 62: 490-2.
15. Dorr RT, Liddil JD. Development of a parenteral formulation of the antitumour agent acronycine. J Drug Dev 1988; 1: 31-9.
16. Costes N, Le Deit H, Michel S, Tillequin F, Koch M, Pfeiffer B, et al. Synthesis and cytotoxic and antitumor activity of benzo[b]pyrano[3,2-h]acridine- 7-one analogues of acronycine. J Med Chem 2000; 43: 2395-402.
17. Doan Thi Mai H, Gaslonde T, Michel S, Tillequin F, Koch M, Bongui JB, et al. Structure-Activity relationships and mechanism of action of antitumor benzo[b]pyrano [3,2-h]acridine-7-one acronycine analogues. J Med Chem 2003; 46: 3072-82.
18. Doan Thi Mai H, Gaslonde T, Michel S, Koch M, Tillequin F, Pfeiffer B, et al. Synthesis and cytotoxic and antitumor activity of 1,2-dihydroxy-1,2- dihydrobenzo[b] acronycine diacid hemiesters and carbamates. Chem Pharm Bull 2004; 52: 293-7.
19. Guilbaud N, Kraus-Berthier L, Meyer F, Tillequin F, Koch M, Pfeiffer B, et al. Preclinical antitumor activity of S 23906-1, a new acronycine derivative in human orthotopic models. Proc Amer Assoc Cancer Res 2000; 41: 600.
20. Guilbaud N, Kraus-Berthier L, Meyer-Loisic F, Malivet V, Chacun C, Jan M, Tillequin F, et al. Marked antitumor activity of a new potent acronycine derivative in orthotopic models of human solid tumors. Clin Cancer Res 2001; 7: 2573-80.
21. Guilbaud N, Léonce S, Tillequin F, Koch M, Hickman JA, Pierré A. Acronycine derivatives as promising antitumor agents. Anti-Cancer Drugs 2002; 13: 445-9.
22. Léonce S, Perez V, Lambel S, Burbridge F, Tillequin F, Koch M, Pfeiffer B, Pierré A, Atassi Gh. Cytotoxicity and cell cycle effect of S 23906-1, a new acronycine derivative. Proc Amer Assoc Cancer Res 2000; 41: 601.
23. Léonce S, Perez V, Lambel S, Peyroulan D, Tillequin F, Michel S, Koch M, Pfeiffer B, Atassi Gh, Hickman J, Pierré A. Induction of cyclin E and inhibition of DNA synthesis by the novel acronycine derivative S23906-1 precede the irreversible arrest of the tumor cells in S phase leading to apoptosis. Mol Pharmacol 2001; 60: 1383-91.
24. Kluza J, Lansiaux A, Wattez N, Hildebrand MP, Léonce S, Pierré A et al. Induction of apoptosis in HL-60 leukemia and B16 melanoma cells by the acronycine derivative S23906-1. Biochem Pharmacol 2002; 63: 1443-52.
25. David-Cordonnier MH, Laine W, Lansiaux A, Kouach M, Briand G, Pierré A et al. Alkylation of guanine in DNA by S23906-1, a novel potent antitumor compound derived from the plant alkaloid acronycine. Biochemistry 2002; 41: 9911-20.
26. David-Cordonnier MH, Laine W, Kouach M, Briand G, Vézin H, Gaslonde T et al. A transesterification reaction is implicated in the covalent binding of benzo[blacronycine anticancer agents with DNA and glutathione. Bioorg Med Chem 2004; 12: 23-9.